Avanos Medical (AVNS) Depreciation & Amortization (CF) (2013 - 2026)

Avanos Medical has disclosed Depreciation & Amortization (CF) across 14 years of filings, most recently posting $10.2 million for Q1 2026.

• Depreciation & Amortization (CF) for Q1 2026 came in at $10.2 million, up 6.25% year-over-year; the trailing twelve-month figure through Mar 2026 was $39.5 million (down 9.61% YoY), and the FY2025 annual result was $38.9 million, down 14.51% from the prior year.
• Depreciation & Amortization (CF) came in at $10.2 million for Q1 2026 at Avanos Medical, up from $9.9 million in the prior quarter.
• In the past five years, Depreciation & Amortization (CF) ranged from a high of $13.4 million in Q4 2022 to a low of $9.4 million in Q3 2025.
• The 5-year median for Depreciation & Amortization (CF) is $11.3 million (2024), against an average of $11.1 million.
• Across the five-year window, Depreciation & Amortization (CF) surged 41.05% in 2022 and decreased 19.66% in 2025, its largest moves.
• Avanos Medical's Depreciation & Amortization (CF) stood at $13.4 million in 2022, then slipped by 14.18% to $11.5 million in 2023, then declined by 3.48% to $11.1 million in 2024, then dropped by 10.81% to $9.9 million in 2025, then increased by 3.03% to $10.2 million in 2026.
• The last three Depreciation & Amortization (CF) figures came in at $10.2 million (Q1 2026), $9.9 million (Q4 2025), and $9.4 million (Q3 2025), per Business Quant data.